Tirzepatide is the most powerful weight-loss medication you can get right now. Here’s a straight comparison between compounded tirzepatide vs Zepbound: what’s the same, what’s not, and how cost, strength, safety, and the legal picture actually shake out. Key takeaways Is compounded tirzepatide the same as Zepbound? Quick answer: Compounded tirzepatide and Zepbound are built […]
By Astra Editorial Team
Medically reviewed by Astra Editorial Team on 2026-08-03
Published:
Updated:
Tirzepatide is the most powerful weight-loss medication you can get right now. Here’s a straight comparison between compounded tirzepatide vs Zepbound: what’s the same, what’s not, and how cost, strength, safety, and the legal picture actually shake out.
Quick answer: Compounded tirzepatide and Zepbound are built on the exact same drug, i.e., tirzepatide, but Zepbound is the version the FDA has reviewed and approved as a finished product.
Zepbound is Eli Lilly’s brand, approved in 2023 for weight management and later for obstructive sleep apnea. Mounjaro is the identical molecule (also from Eli Lilly) but sold for type 2 diabetes. Compounded tirzepatide is that same dual GLP-1/GIP medication, mixed by a licensed pharmacy for one person at a time.
Same active ingredient. One flat price no matter where your dose lands.
Start your health profile →| Compounded tirzepatide | Zepbound | |
|---|---|---|
| Active ingredient | Tirzepatide | Tirzepatide |
| FDA-approved finished product | No | Yes |
| Approved to treat | Not FDA-approved (prescribed off-label for weight) | Weight management; obstructive sleep apnea with obesity |
| Who makes it | A licensed compounding pharmacy, per prescription | Eli Lilly |
| How you take it | Draw from a vial into a syringe | Single-dose vial or pre-filled pen |
| Dosing | Flexible; often one flat price across doses | Fixed strengths (2.5-15 mg); cash price rises by dose |
| Cost per month (cash) | ~$125-$400 | ~$299-$1,086 |
| Legal status (Aug 2026) | Legal via 503A pharmacies with a patient-specific reason | Fully approved |
Quick answer: Compounded tirzepatide runs about $125-$400 a month, usually at one flat rate. Zepbound’s cash price starts lower but steps up as your dose increases.
Tirzepatide isn’t one dose. You start at 2.5 mg and titrate up over months, potentially to 15 mg. With Zepbound’s self-pay vials on LillyDirect, the price tracks your dose:
| Zepbound dose (cash, single-dose vials) | Price/month |
|---|---|
| 2.5 mg (starting) | $299 |
| 5 mg | $399 |
| 7.5-15 mg | $449 (with on-time refills) |
| 7.5-15 mg, standard price | up to $1,049 (15 mg) |
The $449 rate for higher doses depends on refilling within 45 days. If you miss the window, the 15 mg vial jumps to over $1,000. Retail pens without any program run around $1,086.
Compounded tirzepatide works differently. Because it’s mixed per prescription, many providers charge one flat monthly price no matter what dose you’re on, so titrating from 2.5 mg to 15 mg doesn’t change your bill.
If you’re pricing options, that flat-vs-climbing difference adds up over a year of treatment, and it’s worth confirming before you commit. (See the full GLP-1 cost breakdown for how insurance and manufacturer programs factor in.)
Quick answer: Strength comes from the molecule, and it’s identical in both compounded tirzepatide and Zepbound. So a correctly made, correctly dosed compounded version is working toward the same results as the brand.
In Zepbound’s trial, patients on 15 mg lost about 21% of their body weight over 72 weeks, and roughly 9 in 10 lost at least 5%. Compared head-to-head with semaglutide, tirzepatide came out ahead, which is why it’s the go-to for those chasing the biggest result. (For that full matchup, see semaglutide vs. tirzepatide.)
There’s less published real-world data on compounded tirzepatide specifically, so the brand trials are the reference point. But since it’s the same active ingredient, that’s the outcome a well-made version aims at.
One thing the trials make clear applies to both: tirzepatide is a long-term treatment. People who stopped regained much of the weight over the following year, while those who kept going held it off and lost a little more. Whichever version you use, staying on it is what protects the result.
Quick answer: Zepbound arrives as a click pen or a single-dose vial; compounded tirzepatide comes as a vial you draw into a syringe.
Either way, tirzepatide is injection-only, so if an oral option is a dealbreaker, semaglutide’s formats are the place to look. The other real difference is ingredients: Zepbound is tirzepatide and nothing else, while some compounders add extras like vitamin B12 to compounded tirzepatide.
Quick answer: The molecule carries the same risks either way; the safety gap is about what’s added to the compounded tirzepatide and how carefully it’s made.
Nausea and other stomach issues during dose increases come from tirzepatide itself, so they show up regardless of who prepared it. The added risks with compounding are pharmacy-side: ingredient sourcing, uneven concentrations, and dosing slips that happen more often with a vial and syringe than a pre-filled pen.
If you’re going the compounded route, here’s what a serious provider looks like:
Some compounders mix compounded tirzepatide with vitamin B12 and market the result as “personalized.” Lilly tested those blends and reported that tirzepatide and B12 can react to create a new impurity that isn’t in the approved drug.
Lilly makes Zepbound, so it’s not a neutral party, but it notified the FDA and published the finding. The clean workaround is to insist on base-only tirzepatide with no add-ins, which sidesteps the reaction entirely. If a provider pushes a blend, ask what it’s for.
Everything else is shared ground: nausea and the other stomach effects come from tirzepatide itself, and the remaining risks (uneven concentrations, dosing slips with a vial and syringe, questionable sourcing) come down to the pharmacy, not the drug.
A rigorous 503A compounding operation with base-only tirzepatide and one consistent concentration closes most of that gap. Zepbound’s built-in edge is simply that it’s FDA-reviewed, standardized, and additive-free by default.
Quick answer: Compounded tirzepatide is still legal for individual prescriptions. A 503A pharmacy can compound it for you today, even as the FDA moves to end bulk production.
Tirzepatide’s story ran slightly ahead of semaglutide’s: its shortage was declared over in December 2024, a couple of months before semaglutide’s, which ended the shortage exception that had allowed large-scale copying.
Then, in April 2026, the FDA proposed keeping tirzepatide off the 503B bulks list, its remaining route to bulk compounding. The comment period closed July 30, 2026, and a final call is pending.
That proposal targets bulk 503B production, not the patient-by-patient 503A route. So tirzepatide prescribed specifically for you, for a documented reason, stays legal right now. If the 503A/503B distinction is new to you, here’s how 503A compounding works.
Quick answer: Look past the price tag to the pharmacy behind it, what’s in the vial, and whether the terms stay honest as your dose changes.
A compounded tirzepatide provider worth using should clear a short checklist:
Astra (try-astra.com) is built around a US-licensed 503A pharmacy, clinician review on every prescription, and flat pricing with no hidden fees and no dose-based hikes. If you’re leaning this way, here’s what to expect in your first month on compounded tirzepatide.
Astra’s compounded tirzepatide is $125/month on the 12-month plan — base-only, flat pricing, US-licensed 503A pharmacy, clinician-reviewed.
Start your health profile Takes about 5 minutes.Almost never. Insurance and manufacturer savings cards apply to FDA-approved products like Zepbound, not compounded versions, so compounded is essentially a cash-pay option. On the upside, the cash price for compounded tirzepatide is a fraction of Zepbound’s, which is why people without GLP-1 coverage often land on it in the first place.
No. Tirzepatide is injection-only, whether it’s Zepbound or compounded. The pill options on the market are semaglutide (Rybelsus) and orforglipron (Foundayo), which are both different drugs.
Not on its own. The low price is because there’s no brand markup, no injector device, and it’s mixed per prescription instead of mass-produced. The actual red flags are different: a provider that won’t name its pharmacy, uses a salt form, or skips a clinician review. Cheap plus transparent is fine. Cheap plus vague is not.
Often, yes. Some people start on Zepbound and move to compounded to hold their results at a lower monthly cost, or vice versa. It’s the same molecule, so your clinician matches the dose and keeps you going.
The current FDA proposal only targets bulk (503B) production, so patient-specific 503A compounding keeps going for now. If that ever changed, the fallback is Zepbound. Its self-pay vials start around $299 a month, and your clinician can move you over without a treatment gap.
This article is for educational purposes only and does not constitute medical advice. Consult a licensed physician regarding any medical condition or treatment.